Podcast Episodes
Back to SearchFirst-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy
How should results of the FLAURA2 clinical trial be applied in practice? The study examined the use of osimertinib plus chemotherapy in the first-lin…
2 years, 4 months ago
What Recent “Outstanding Results” in MCL Mean for Practice
“Therapies are improving dramatically” in mantle cell lymphoma (MCL),
according to Michael Wang, MD, professor in the department of
lymphoma/myelom…
2 years, 5 months ago
The Quest to Cure CLL: “Remarkable” Results With New Strategy
Recent advances have provided new options for when and how best to treat patients with chronic lymphocytic leukemia (CLL). Trials of combination stra…
2 years, 6 months ago
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?
The World Conference on Lung Cancer (World Lung) will be held in Singapore, September 9–12. The current president of International Association for th…
2 years, 7 months ago
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
Updates to the American Society for Clinical Oncology’s (ASCO’s) living guidelines for therapy in patients with stage IV non-small cell lung cancer (…
2 years, 7 months ago
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists
In early July, beloved surgeon and breast cancer advocate Susan Love, MD, MBA, died at age 75 years, after a recurrence of leukemia. Dr. Love’s legac…
2 years, 8 months ago
Will HER3 Targeting Change Breast Cancer Care?
HER2 inhibitors dramatically changed care for many breast cancers; however, less is known about HER3, which acts in concert with HER2. Does HER3 have…
2 years, 9 months ago
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now
Although findings have suggested that adjuvant osimertinib is beneficial in early-stage non-smallcell lung cancer (NSCLC), some concerns have persi…
2 years, 9 months ago
“Don’t Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer
How should community oncologists best approach ESR1 mutations in breast cancer, given the latest findings? Recent data presented at the 2023 American…
2 years, 9 months ago
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
Recent results demonstrated that mRNA vaccination improved recurrence-free survival among patients with melanoma. This has led to questions about wh…
2 years, 10 months ago